However, the expression profile of TNF-α receptors on the analyzed T cell subsets was sustained in RA patients receiving adalimumab, as patients’ basal levels and percentages of Th1 and Th17 cells expressing either TNFR1 or TNFR2 were not altered by therapeutic neutralization of TNF-α. Here, TNFRSF1A is linked to rheumatoid arthritis.